Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
131.20
+0.48 (+0.37%)
Official Closing Price
Updated: 7:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Merck & Co
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Seramount Names Merck As One of the 2021 Best Companies for Dads
November 12, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Topics
Economy
Exposures
COVID-19
Interest Rates
Merck Announces Initiation of Phase 3 Study Evaluating VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction Who Have Not Had a Recent Worsening Heart Failure Event
November 11, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck and Ridgeback Announce U.S. Government to Purchase 1.4 Million Additional Courses of Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults
November 09, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck and Ridgeback Announce Japanese Government to Purchase 1.6 Million Courses of Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, Upon Authorization or Approval
November 10, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Receipt of Antitrust Clearance in Germany and Austria Relating to Tender Offer to Acquire Acceleron Pharma Inc.
November 08, 2021
From
Merck & Co., Inc.
Via
Business Wire
Global COVID-19 Therapeutics Market Size Now Expected To Exceed $25 Billion In 2030
November 09, 2021
Palm Beach, FL – November 9, 2021 – FinancialNewsMedia.com News Commentary – The increasing outbreak of covid-19 is increasing the demand for coronavirus vaccines or therapies, which will result in the...
Via
FinancialNewsMedia
Topics
Death
Exposures
COVID-19
Death
The $11 Trillion Healthcare Industry Is About To Change Forever
November 04, 2021
FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – November 4, 2021 – The $11-trillion healthcare industry is going fully digital, disrupting industry giants & government...
Via
FinancialNewsMedia
Merck and Ridgeback’s Molnupiravir, an Oral COVID-19 Antiviral Medicine, Receives First Authorization in the World
November 04, 2021
From
Merck & Co., Inc.
Via
Business Wire
The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, to Increase Broad Access in Low- and Middle-Income Countries
November 01, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
New Research for KEYTRUDA® (pembrolizumab) at Society for Melanoma Research (SMR) 2021 Congress Reinforces Merck’s Commitment to Patients With Melanoma Across Stages of Disease
October 31, 2021
From
Merck & Co., Inc.
Via
Business Wire
Global Metastatic Cancer Treatment Market Size Is Forecasted To Reach $111.16 Million By 2027
November 03, 2021
Palm Beach, FL – November 3, 2021 – FinancialNewsMedia.com News Commentary – The metastatic cancer treatment systems market is observing high demand attributed to its increasing application in breast,...
Via
FinancialNewsMedia
Merck Announces Withdrawal and Refiling under the Hart-Scott-Rodino Act and Extension of Tender Offer to Acquire Acceleron Pharma Inc.
October 29, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Third-Quarter 2021 Financial Results
October 28, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Presents New Data from Ongoing Phase 2b Clinical Trial Evaluating Efficacy and Safety of Investigational Islatravir in Combination With Doravirine Through 144 Weeks for HIV-1 Treatment at EACS 2021
October 27, 2021
From
Merck & Co., Inc.
Via
Business Wire
The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, to Increase Broad Access in Low- and Middle-Income Countries
October 27, 2021
From
Merck & Co., Inc.
Via
Business Wire
Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults
October 26, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection
October 25, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck and Ridgeback Announce Initiation of a Rolling Review by the European Medicines Agency for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of COVID-19 in Adults
October 25, 2021
From
Merck & Co., Inc.
Via
Business Wire
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC)
October 22, 2021
From
Merck & Co., Inc.
Via
Business Wire
CDC ACIP Unanimously Votes to Provisionally Recommend Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Series with PNEUMOVAX ® 23 (Pneumococcal Vaccine Polyvalent) as an Option for Pneumococcal Vaccination in Appropriate Adults
October 20, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Issues Voluntary Nationwide Recall of CUBICIN® (daptomycin for injection) 500 mg, Lot 934778, Due to Presence of Particulate Matter Identified as Glass Particles
October 19, 2021
From
Merck & Co., Inc.
Via
Business Wire
Is This The Most Exciting Medical Breakthrough Of The Decade
October 19, 2021
FN Media Group Presents Oilprice.com Market Commentary London – October 19, 2021 – According to Google’s Health boss David Feinberg… over one billion people a day search Google for health concerns....
Via
FinancialNewsMedia
6 Global Trends Critical to Patients During the COVID-19 Pandemic
October 18, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Exposures
COVID-19
Merck and Eisai Receive Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Two Different Types of Cancer
October 15, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Individuals 18 Years of Age and Older
October 15, 2021
From
Merck & Co., Inc.
Via
Business Wire
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)
October 13, 2021
From
Merck & Co., Inc.
Via
Business Wire
Humans, Animals and the Environment - Our Health Is All Connected
October 13, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Topics
Climate Change
Exposures
Climate
Merck Begins Tender Offer to Acquire Acceleron Pharma Inc.
October 12, 2021
From
Merck & Co., Inc.
Via
Business Wire
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
October 11, 2021
Palm Beach, FL –October 11, 2021 – FinancialNewsMedia.com News Commentary – With the arrival of the COVID-19 virus, the antivirals market had all eyes watching the ongoing frenetic rush to find a cure...
Via
FinancialNewsMedia
Exposures
COVID-19
U.S. Is Dominating Psychedelic Drugs Market Due To Growing Acceptance For Treating Depression & Rise In Product Approvals
October 12, 2021
Palm Beach, FL –October 12, 2021 – FinancialNewsMedia.com News Commentary – After being relegated to the margins of sincere scientific examination for about the last several decades, growing...
Via
FinancialNewsMedia
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.